Vivoryon Therapeutics NV (VVY) - Total Assets
Based on the latest financial reports, Vivoryon Therapeutics NV (VVY) holds total assets worth €7.52 Million EUR (≈ $8.79 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Vivoryon Therapeutics NV shareholders equity for net asset value and shareholders' equity analysis.
Vivoryon Therapeutics NV - Total Assets Trend (2010–2025)
This chart illustrates how Vivoryon Therapeutics NV's total assets have evolved over time, based on quarterly financial data.
Vivoryon Therapeutics NV - Asset Composition Analysis
Current Asset Composition (December 2025)
Vivoryon Therapeutics NV's total assets of €7.52 Million consist of 85.5% current assets and 14.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 74.7% |
| Accounts Receivable | €142.00K | 1.9% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €797.00K | 10.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Vivoryon Therapeutics NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VVY market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vivoryon Therapeutics NV's current assets represent 85.5% of total assets in 2025, an increase from 47.5% in 2010.
- Cash Position: Cash and equivalents constituted 74.7% of total assets in 2025, up from 38.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 42.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 10.6% of total assets.
Vivoryon Therapeutics NV Competitors by Total Assets
Key competitors of Vivoryon Therapeutics NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
USA | $107.75 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bio-Thera Solutions Ltd
SHG:688177
|
China | CN¥2.39 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Gubra A/S
CO:GUBRA
|
Denmark | Dkr1.32 Billion |
Vivoryon Therapeutics NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.68 | 7.20 | 21.73 |
| Quick Ratio | 7.68 | 7.20 | 21.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €5.59 Million | €8.67 Million | €27.47 Million |
Vivoryon Therapeutics NV - Advanced Valuation Insights
This section examines the relationship between Vivoryon Therapeutics NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.02 |
| Latest Market Cap to Assets Ratio | 5.04 |
| Asset Growth Rate (YoY) | -33.4% |
| Total Assets | €7.52 Million |
| Market Capitalization | $37.91 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Vivoryon Therapeutics NV's assets at a significant premium (5.04x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Vivoryon Therapeutics NV's assets decreased by 33.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vivoryon Therapeutics NV (2010–2025)
The table below shows the annual total assets of Vivoryon Therapeutics NV from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €7.52 Million ≈ $8.79 Million |
-33.37% |
| 2024-12-31 | €11.28 Million ≈ $13.19 Million |
-63.40% |
| 2023-12-31 | €30.83 Million ≈ $36.04 Million |
-1.75% |
| 2022-12-31 | €31.38 Million ≈ $36.68 Million |
+27.97% |
| 2021-12-31 | €24.52 Million ≈ $28.67 Million |
-17.58% |
| 2020-12-31 | €29.75 Million ≈ $34.78 Million |
-35.13% |
| 2019-12-31 | €45.86 Million ≈ $53.62 Million |
+1132829.84% |
| 2018-12-31 | €4.05K ≈ $4.73K |
-62.39% |
| 2017-12-31 | €10.76K ≈ $12.58K |
-51.88% |
| 2016-12-31 | €22.37K ≈ $26.15K |
+2.29% |
| 2015-12-31 | €21.87K ≈ $25.56K |
+1.80% |
| 2014-12-31 | €21.48K ≈ $25.11K |
-99.66% |
| 2013-12-31 | €6.37 Million ≈ $7.45 Million |
-36.29% |
| 2012-12-31 | €10.01 Million ≈ $11.70 Million |
-47.60% |
| 2011-12-31 | €19.09 Million ≈ $22.32 Million |
+19.59% |
| 2010-12-31 | €15.97 Million ≈ $18.67 Million |
-- |
About Vivoryon Therapeutics NV
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical tr… Read more